Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (10129)	7/2/2007 12:00:25 PM
From: tuck	Read Replies (1) \| Respond to of 10280

Righto, well, it turns out the reason we haven't dissected Sanofi's data on Eplivanserin is because they haven't released any. It's being tried against schizophrenia, too, and it whiffed in sleep apnea. Sanofi hasn't published anything about Eplivanserin in human sleep studies (there's a fair amount of animal data out there, but I think it mostly relates to basic MOA and schizophrenia) but a few sentences saying it increased TST and had good WASO numbers -- without actually giving the numbers. Can't find any abstracts on the P2b trials. Big pharma, playing close the vest. Cheers, Tuck